The oral iron chelator deferiprone has been shown to be more effective at reducing myocardial iron load than subcutaneous desferrioxamine. The clinical benefit was significantly improved ventricular function in the deferiprone group.
Ref:
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia (2002). Lisa J Anderson, Beatrix Wonke, Emma Prescott, Sally Holden, J Malcolm Walker, Dudley J Pennell. Lancet 2002; 360: 516-20
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.